I think this might be the update Prof MP did late last year, you might be referring to: https://images.app.goo.gl/zPGAh7NzTeYur4aq7
"This drug is incredibly well tolerated, so patients really have a very good quality of life."
"Responses seen in a variety of t-cell lymphomas. So, its exciting to see.... There's nothing worse than having a really good drug that patients can't tolerate."
"Its been really rewarding working with the drug that we hope one day will become standard therapy."
We're with you on this, Prof Prince!
Ann: PTX-100 receives U.S. FDA Fast Track Designation, page-78
Add to My Watchlist
What is My Watchlist?
